FOXP3–Helios Engineered Tregs for Stable Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Treg therapies face challenges in isolating and expanding Tregs to sufficient numbers, and engineered Tregs (eTregs) often fail to maintain effective immunosuppressive function, particularly in treating conditions like GVHD.
Innovation Solution
The generation of engineered regulatory T cells (eTregs) with ectopic overexpression of FOXP3 and Helios, achieved through sequential transduction of total T cell populations using separate nucleic acid constructs, ensures stable co-expression and higher numbers of CD4+ and CD8+ eTregs, enhancing immunosuppressive efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Tregs are isolated from patients or third-party sources and expanded ex vivo, then Treg therapy can be administered, but it is difficult to expand Tregs to sufficient numbers and maintain their immunosuppressive function
Solution Approach 1:
The patent changes the genetic parameters of T cells by introducing exogenous FOXP3 and Helios genes through lentiviral transduction. This genetic modification transforms conventional T cells into engineered Tregs with enhanced and stable immunosuppressive function, solving the problem of maintaining reliability during expansion
Solution Approach 2:
The patent performs preliminary genetic modification of T cells before expansion therapy. By pre-installing the FOXP3 and Helios transgenes through lentiviral transduction, the cells are prepared in advance to maintain stable immunosuppressive function throughout the expansion process and after infusion
2Quantity of substance
If conventional T cells are transduced with FOXP3 to create eTregs, then higher numbers of eTregs can be produced, but stable co-expression of FOXP3 and Helios is difficult to achieve
Solution Approach 1:
The patent combines FOXP3 and Helios transgenes into a single lentiviral vector construct. This merging approach ensures that both genes are delivered simultaneously to the same T cells, achieving stable co-expression and avoiding the variability associated with separate transduction protocols
Solution Approach 2:
The patent creates a composite genetic construct containing both FOXP3 and Helios coding sequences along with appropriate regulatory elements. This composite transgene design ensures coordinated expression of both proteins, achieving stable co-expression in the engineered Tregs
3Ease of manufacture
If Tregs are isolated using CD4+ CD25+ markers, then Treg selection is simplified, but activated conventional T cells are also selected leading to contamination
Solution Approach 1:
The patent extracts the limiting step of Treg purification by using lentiviral transduction to mark modified cells with a unique surface antigen. This allows subsequent easy separation of engineered Tregs from unmodified cells, achieving high purity without complex isolation procedures
Solution Approach 2:
The patent introduces an intermediary selection mechanism using a lentiviral transgene that expresses a unique surface antigen. This intermediary marker serves as a reliable identifier for purified eTregs, enabling precise separation from contaminating conventional T cells through flow cytometry or magnetic sorting
4Reliability
If FOXP3 is overexpressed in T cells, then immunosuppressive function is enhanced, but the phenotype becomes unstable and Tregs can convert to Tconvs
Solution Approach 1:
The patent changes the genetic composition by introducing not only FOXP3 but also Helios, a transcription factor that stabilizes Treg phenotype. This dual genetic modification creates a more stable engineered Treg phenotype that resists conversion to conventional T cells while maintaining enhanced immunosuppressive function
Solution Approach 2:
The patent creates a composite genetic system containing both FOXP3 and Helios transgenes that work synergistically. This composite approach provides mutual reinforcement of Treg phenotype stability, preventing spontaneous conversion to Tconvs while maintaining enhanced immunosuppressive activity
Data Source
AI summary
Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+ eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.